Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 352

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 352
---
2023 warrants

In December 2023
the Company issued 3,000,063 Series E ADS Warrants and 3,000,063 Series F ADS Warrants as part of the Registered Offering in the US. The
exercise price per ADS is $2.20.

May 2023 warrants

In June 2023 the
Company issued 276,689 Series D ADS Warrants as part of a registered direct offering and private placement in the US after securing shareholder
approval. The exercise price per ADS was $16.00.

May 2020 warrants

In May 2020 the
Company issued 838 ADS warrants as part of a registered direct offering in the US.

October 2019 warrants

In October 2019
the Company issued 392 ADS warrants as part of a registered direct offering in the US.

| F-12 |

Warrant re-price

On May 22, 2024 the Company entered
into agreements with several accredited investors to exercise existing Series E warrants and Series F warrants, issued in December 2023,
to purchase up to an aggregate of 4,358,322 ADSs. The warrant holders agreed to exercise the Series E and/or Series F warrants at an exercise
price of $1.50 (reduced from $2.20) per ADS.

| Schedule of warrant exercise price |     | ADS Warrants Number |     |   | Original price per 
                ADS |     |   | New price per ADS |     |      Equivalent Ordinary 
     Shares (400 Ordinary 
 Shares per ADS)   Number |
|:-----------------------------------|:----|--------------------:|:----|:--|-------------------:|:----|:--|------------------:|:----|-------------------------:|
| Series E warrants                  |     |           1,572,674 |     | $ |               2.20 |     | $ |              1.50 |     |              629,069,600 |
| Series F warrants                  |     |           2,463,477 |     | $ |               2.20 |     | $ |              1.50 |     |              985,390,800 |

Warrants and Dara share options

The Group also
assumed fully vested warrants and share options on the acquisition of DARA Biosciences, Inc. (which took place in 2015). The number of
ordinary shares to be issued when exercised is fixed, however the exercise prices